Abstract
A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32% for epirubicin and 30% for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.
| Original language | English |
|---|---|
| Pages (from-to) | 131-137 |
| Number of pages | 7 |
| Journal | Clinical Trials Journal |
| Volume | 24 |
| Issue number | SUPPL. 1 |
| Publication status | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin) : Preliminary report of the EORTC breast cancer cooperative group. / Van Oosterom, A. T.; Mouridsen, H. T.; Wildiers, J.; Blonk-Van Der Wijst, J.; Cocconi, G.; Beex, L. V M; Rotmensz, N.; Sylvester, R.
In: Clinical Trials Journal, Vol. 24, No. SUPPL. 1, 1987, p. 131-137.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Advanced breast cancer. A comparative evaluation of epirubicin and doxorubicin (Adriamycin)
T2 - Preliminary report of the EORTC breast cancer cooperative group
AU - Van Oosterom, A. T.
AU - Mouridsen, H. T.
AU - Wildiers, J.
AU - Blonk-Van Der Wijst, J.
AU - Cocconi, G.
AU - Beex, L. V M
AU - Rotmensz, N.
AU - Sylvester, R.
PY - 1987
Y1 - 1987
N2 - A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32% for epirubicin and 30% for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.
AB - A preliminary report on an uncompleted Phase III study following results obtained from a Phase II study is presented. In the Phase II study epirubicin 90 mg/m2 i.v. every three weeks and doxorubicin (Adriamycin) 75 mg/m2 i.v. every three weeks were given, the myelotoxicity expected and found being approximately the same for each group. There were two complete and eight partial responses obtained in the epirubicin group of 31 patients and five complete and five partial responses obtained from the 33 patients on doxorubicin. The median duration of complete response in the epirubicin group was 38 1/2 weeks and 24 weeks for doxorubicin. The overall response rate was 32% for epirubicin and 30% for doxorubicin. In the Phase III study, 30 patients out of 90 have given responses - seven complete, 23 partial. Only two patients on epirubicin and four on doxorubicin had a nadir platelet count below 50,000. With respect to myelotoxicity the dosages of 90 and 75 mg/m2 for epirubicin and doxorubicin respectively appeared to be adequate. The antitumour activities of both compounds appear to be equal. Oral toxicity and diarrhoea appear to be slightly less with epirubicin.
UR - http://www.scopus.com/inward/record.url?scp=0023606104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023606104&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0023606104
VL - 24
SP - 131
EP - 137
JO - Clinical Trials Journal
JF - Clinical Trials Journal
SN - 0009-9325
IS - SUPPL. 1
ER -